GREENLAND MINES LTD Franchisor Costs
GREENLAND MINES LTD (GRML) reported Franchisor Costs of $33.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FranchisorCosts · last filed 2023-11-17
- GREENLAND MINES LTD franchisor costs for the quarter ending 2023-09-30 was $33.00K, a 16.03% decline year-over-year.
- GREENLAND MINES LTD franchisor costs for the quarter ending 2023-06-30 was $33.90K, a 13.74% decline year-over-year.
- GREENLAND MINES LTD franchisor costs for the quarter ending 2023-03-31 was $32.10K.
- GREENLAND MINES LTD franchisor costs for the quarter ending 2022-12-31 was $44.20K.
- GREENLAND MINES LTD franchisor costs for fiscal 2022 was $123.03K.
| Period end | Franchisor Costs 3 month | Franchisor Costs 6 month | Franchisor Costs 9 month | Franchisor Costs 12 month |
|---|---|---|---|---|
| 2023-09-30 | $33.00K 10-Q · filed 2023-11-17 | $66.90K derived: sum of 2 quarters · filed 2023-11-17 | $99.00K 10-Q · filed 2023-11-17 | $143.20K derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | $33.90K 10-Q · filed 2023-08-21 | $66.00K 10-Q · filed 2023-08-21 | $110.20K derived: sum of 3 quarters · filed 2023-10-18 | $149.50K derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-03-31 | $32.10K 10-Q · filed 2023-05-24 | $76.30K derived: sum of 2 quarters · filed 2023-10-18 | $115.60K derived: sum of 3 quarters · filed 2023-11-17 | $154.90K derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-12-31 | $44.20K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-10-18 | $83.50K derived: sum of 2 quarters · filed 2023-11-17 | $122.80K derived: sum of 3 quarters · filed 2023-11-17 | $123.03K 10-K/A · filed 2023-10-18 |
| 2022-09-30 | $39.30K 10-Q · filed 2023-11-17 | $78.60K derived: sum of 2 quarters · filed 2023-11-17 | $78.83K 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $39.30K 10-Q · filed 2023-08-21 | $39.30K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |